NCT02362867

Brief Summary

The protocol will define the clinical study for Ortho Development's Balanced Knee® System (BKS) for subsequent review and approval by an Institutional Review Board (IRB).This clinical study will compare the clinical outcomes of BKS to currently marketed devices.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
500

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jan 2003

Longer than P75 for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2003

Completed
12.1 years until next milestone

First Submitted

Initial submission to the registry

February 9, 2015

Completed
4 days until next milestone

First Posted

Study publicly available on registry

February 13, 2015

Completed
4.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 2, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 2, 2019

Completed
Last Updated

September 24, 2021

Status Verified

September 1, 2021

Enrollment Period

16.4 years

First QC Date

February 9, 2015

Last Update Submit

September 23, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Evaluate effectiveness of the BKS by assessing complications during surgery and the post-operative follow-up period

    1-10 years

Secondary Outcomes (3)

  • Assess the effectiveness of the BKS by analyzing radiographic evidence and clinical data.

    1-10 years

  • Identify any surveillance issues regarding the device design and surgical approach used refinement of the surgical technique

    1-10 years

  • Evaluate device performance through the use of the Knee Society Score, Short Form-36 Health Survey, and radiographic evaluation.

    1-10 years

Study Arms (1)

Total Knee Replacement

NO INTERVENTION

Total knee replacement is indicated for patients suffering from severe knee pain and disability. Specific indications include femoral, tibial and patellar replacement due to degenerative bone disease such as osteoarthritis, rheumatoid arthritis, primary and secondary traumatic arthritis, polyarthritis, collagen disorders, avascular necrosis of the femoral condyles, or complications from a previous prosthesis. The Balanced Knee System (BKS) will be used to treat patients undergoing a total knee replacement.

Device: Balanced Knee System

Interventions

A multi-compartmental total knee replacement providing a system of components for primary posterior cruciate ligament substituting procedures. The system consists of femoral, tibial, and patellar components that allow the surgeon to select the most appropriate component combination to meet specific patient needs.

Also known as: BKS
Total Knee Replacement

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Loss of joint configuration and joint function.
  • Osteoarthritis of the knee joint.
  • Rheumatoid arthritis of the knee joint.
  • Post-traumatic arthritis of the knee joint.
  • Moderate valgus, varus, or flexion deformities.

You may not qualify if:

  • Any patient not experiencing a compromised quality of life by loss of joint function and/or joint configuration, or pain from arthritis disease.
  • Any patient whose knee cannot be returned to normal function and normal stability through reconstructive procedures, including ligamentous balancing.
  • Active infection in or near the knee joint, fever and/or local inflammation signs, and elevation of sedimentation rate unexplained by other diseases should not be treated unless preoperative infection is ruled out.
  • Distant foci of infection, such as genitourinary, pulmonary, skin (chronic lesions or ulcerations), and other sites, which may result in hematogenous spread to the implant site.
  • Rapid joint destruction or bone absorption apparent on roentgenograms.
  • Neuromuscular disorders in which the potentially adverse effects on prosthesis function are not outweighed by the benefits gained by the patient from usage of the prosthesis.
  • Mental disorders which would compromise essential patient post-operative care.
  • A painless, stable arthrodesis in a functional position.
  • Allergic reactions to implant materials, and/or tissue reactions to the products of corrosion or wear.
  • Skeletal immaturity.
  • Any patient who is unwilling or unable to comply with post-operative instructions or clinical study requirements.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Osteoarthritis, Knee

Condition Hierarchy (Ancestors)

OsteoarthritisArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Study Officials

  • Michael H. Bourne, M.D.

    Salt Lake Orthopaedic Clinic

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 9, 2015

First Posted

February 13, 2015

Study Start

January 1, 2003

Primary Completion

June 2, 2019

Study Completion

June 2, 2019

Last Updated

September 24, 2021

Record last verified: 2021-09